Navigation Links
Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
Date:8/19/2007

CARLSBAD, Calif., Aug. 17 /PRNewswire/ -- AutoGenomics, a leader in developing automated molecular testing solutions, announced today that its CYP450 2C9-VKORC1 panel that it submitted to the FDA for 510(k) clearance late last year, has now been evaluated by the Harvard Medical School-Partners HealthCare Center for Genetics and Genomics (HPCGG).

Warfarin (also called Coumadin) is a drug prescribed to help prevent blood clots. With more than 2 million prescriptions per year, one of the side effects of the drug is an increased risk of bleeding. The FDA re-labeled yesterday the warfarin package insert recommending the testing of multiple genetic variants in two genes namely 2C9 and VKORC1 for safer drug dosing.

"We have completed a successful evaluation of the INFINITI 2C9-VKORC1 panel which has the potential to optimize warfarin dosing and lower the risk of bleeding complications" said Dr. Raju Kucherlapati, Scientific Director of the Harvard Medical School-Partners HealthCare Center for Genetics and Genomics (HPCGG) in Cambridge, Massachusetts. HPCGG is coordinating the "CReating an Optimal Warfarin Nomogram" (CROWN) Trial which is a prospective dosing study utilizing genetic testing to determine the optimal warfarin dose and how this information can be used for clinical care.

"We are pleased to see that through the re-labeling of the warfarin package insert, the FDA has recognized that patients with certain genetic variants may benefit from lower initial dosage thus reducing the risk of major bleeding events" said Ram Vairavan, Senior Vice President at AutoGenomics. He further said "Our expanded panel of genetic variants mentioned in the package insert encompassing African, Asian and other ethnic groups enables same day dosing on our automated multiplexing platform."

About AutoGenomics

AutoGenomics Inc., a privately held company based in Carlsbad, CA, has developed the first automated, microarray based multiplexing diagnostic platforms that can be used to assess disease signatures with novel genomic and proteomic markers in the area of genetic disorders, infectious disease, cancer and pharmacogenetics. With the discovery of genes and their link to various disease states the platform has the versatility to revolutionize the way patients are diagnosed, monitored and managed leading to the era of personalized medicine. http://www.autogenomics.com


'/>"/>
SOURCE AutoGenomics Inc

Copyright©2007 PR Newswire.

Related medicine technology :

1. Antidepressant Use May Boost Fracture Risk, From Harvard Womens Health Watch
2. Bipolar Disorder in Children Difficult to Diagnose, Reports the Harvard Mental Health Letter
3. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
4. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
5. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
6. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
7. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
8. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
9. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
10. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
11. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 4, 2016  Omnicell, Inc. (NASDAQ: OMCL ), a ... healthcare systems, today announced results for its fiscal year ... --> --> GAAP results: Revenue for ... $5.1 million or 4.1% from the third quarter of ... fourth quarter of 2014. Revenue for the year ended ...
(Date:2/4/2016)... Feb. 4, 2016 In response to the opioid ... Deputy Commissioner for Medical Products and Tobacco, along with other ... the agency,s approach to opioid medications. The plan will focus ... patients in pain access to effective relief. ... , Re-examine the risk-benefit paradigm for opioids and ensure ...
(Date:2/4/2016)... -- --> --> ... Automated External Defibrillator (AED) Market by Product (Semi-Automated External ... Hospitals, Homecare & Nursing Homes) - Forecast to 2019", ... and segments the concerned market with an analysis and ... grow to about $367.0 million by 2019, at a ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... , ... The event is being held on April 7, 2016 from 5:30 ... Over Parkinson’s will fund nearly $100,000 for research for the care and cure of ... and is the architect of this informative event to raise awareness and funds for ...
(Date:2/5/2016)... ... February 05, 2016 , ... Freed-Hardeman University President Joe ... signed a joint enrollment and degree completion agreement. The agreement, which begins ... degrees at FHU|Dickson. , The agreement allows students to be jointly admitted ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... franchises from across the country gathered at the La Valencia Hotel in San ... PROSHRED Chicago was named the year’s most outstanding franchise, walking away with ...
(Date:2/5/2016)... ... February 05, 2016 , ... Boar’s Head Brand®, one ... time for this weekend’s Big Game. Take the stress out of your party preparation ... your guests happy at every stage of the game. , “The key to hosting ...
(Date:2/5/2016)... ... February 05, 2016 , ... Stuart Bentkover, MD, FACS is ... to provide the most effective tattoo removal today, Dr. Bentkover is the only doctor ... by Cynosure, the PicoSure has been approved by the Food and Drug Administration (FDA) ...
Breaking Medicine News(10 mins):